Medicare has changed the accounting rules for one of the least visible parts of the transplant system: the money spent recovering an organ before it ever reaches a surgeon.
In the inpatient payment rule finalized on July 31, the Centers for Medicare & Medicaid Services said it will "reconcile organ acquisition costs for non-renal organs" for independent organ procurement organizations and histocompatibility laboratories. The agency modified its original proposal to delay implementation by two years, applying to cost reporting periods beginning on or after October 1, 2028.
For patients on a transplant waiting list, the honest summary is that this is a cost accounting and payment integrity measure, and CMS has not projected any effect on organ availability or wait times. That is worth saying at the top, because rules touching transplant tend to generate more alarm than their contents warrant.
The Accounting Change, Stated Plainly
Reconciliation means comparing what an organization was paid during a period against what its actual allowable costs turned out to be, and settling the difference.
CMS finalized this for non-renal organs, meaning organs other than kidneys, handled by independent organ procurement organizations and by histocompatibility laboratories, which perform the tissue typing and compatibility testing that determines whether a donor organ matches a recipient. Kidney acquisition costs have long been subject to their own reconciliation framework.
The rule does two other things in the same area. It codifies longstanding policies on what counts as an allowable cost under Medicare's reasonable cost principles across all provider types, including public education activities conducted by organ procurement organizations. And it codifies how overhead costs are allocated across provider types.
Separately, the rule codifies the CMS Administrator's discretionary review of reimbursement appeals filed by these organizations and laboratories, which formalizes an existing step in the appeals process rather than creating a new one.
The agency framed the package as part of a broader effort to strengthen cost reimbursement and appeals policies to improve payment accuracy and reduce inappropriate spending. The full rule is available as Federal Register document 2026-15833, summarized in the CMS fact sheet.
The Organizations Between a Donor and a Recipient
Most people never encounter an organ procurement organization by name, which is part of why a rule about their cost reporting reads as opaque.
These are federally designated nonprofits, each responsible for a defined geographic service area. When a potential donor is identified in a hospital, the organization evaluates medical suitability, approaches the family about donation, manages the donor clinically while arrangements are made, coordinates the matching process, arranges surgical recovery of the organs and handles transport to transplant centers.
That work happens on compressed timelines and generates substantial cost regardless of whether a transplant ultimately occurs. A donor evaluation that does not result in a usable organ still consumes staff time, testing and clinical resources.
Histocompatibility laboratories do the immunologic matching. Their testing determines whether a recipient's immune system is likely to reject a particular donor organ, which is why the work sits on the critical path of every transplant.
Separate Payment for Organ Acquisition Has a Long History
Organ acquisition is reimbursed outside the standard inpatient payment that covers a transplant hospitalization, and the reason is structural.
A hospital paid a single bundled amount for a transplant would be absorbing the cost of an entire donor recovery operation that happened elsewhere, often in another facility and sometimes in another state, and whose cost varies enormously case by case. Separating acquisition costs and reimbursing them on a reasonable cost basis was intended to keep that variability from distorting incentives around which patients get transplanted.
The tradeoff is that reasonable cost reimbursement requires oversight to confirm that reported costs are actually allowable and correctly allocated. Reconciliation is that oversight mechanism. Extending it to non-renal organs applies to hearts, livers, lungs and pancreata a scrutiny that already existed for kidneys.
Effects on Waiting Lists Have Not Been Projected
This is the question the rule does not answer, and it would be misleading to suggest otherwise.
CMS did not publish an estimate of how the change would affect the number of organs recovered, the number of transplants performed, or the time patients spend waiting. The rule governs how costs are reported and settled after the fact. It does not change clinical criteria for donation, allocation policy determining who receives an available organ, or the coverage a patient has for a transplant.
Two possibilities are worth holding at once without treating either as established. Tighter cost reconciliation could constrain what procurement organizations spend on activities at the margin, including outreach and education, which is a concern the sector has raised in comment periods on cost policy generally. It could equally have no observable effect on operations. There is no post-implementation data because implementation begins in late 2028, and the two-year delay CMS granted is itself an acknowledgment that organizations need time to adjust their accounting.
Patients waiting for a transplant should not change anything based on this rule. Questions about individual waiting status, listing at multiple centers or evaluation timelines belong with a transplant coordinator or nephrologist, hepatologist or cardiologist managing the case.
Implementation Runs Through 2028
The reconciliation requirement applies to cost reporting periods beginning on or after October 1, 2028. The codification provisions on allowable costs, overhead allocation and Administrator review take effect with the rest of the rule.
Whether CMS publishes analysis of the effects once data exists is not something the agency has committed to.
The confirmed fact is that Medicare will reconcile non-renal organ acquisition costs for independent procurement organizations and histocompatibility laboratories starting with cost reporting periods that begin in late 2028. The people most directly affected are those organizations and the laboratories, not patients. The most reasonable action for anyone awaiting a transplant is none, beyond continuing with their transplant center. The central uncertainty is whether tighter cost oversight changes procurement organization operations in any way patients would notice, which no available evidence addresses.
Frequently Asked Questions
What did CMS finalize?
Medicare will reconcile organ acquisition costs for non-renal organs for independent organ procurement organizations and histocompatibility laboratories, with implementation delayed to cost reporting periods beginning on or after October 1, 2028. The rule also codifies allowable cost policies, overhead allocation and the Administrator's review of reimbursement appeals.
What is an organ procurement organization?
A federally designated nonprofit responsible for a geographic area that evaluates potential donors, approaches families, coordinates matching, arranges surgical recovery and manages transport to transplant centers.
What is a histocompatibility laboratory?
A laboratory that performs tissue typing and compatibility testing to determine whether a donor organ is likely to be accepted by a specific recipient's immune system.
Why are organ acquisition costs paid separately?
Because they are incurred outside the transplant hospitalization, often at another facility, and vary widely case by case. Bundling them into a single transplant payment would create distorted incentives.
Will this affect how long I wait for a transplant?
CMS has not projected any effect on organ availability or wait times. The rule governs cost reporting and settlement, not clinical criteria or organ allocation.
Does this change my Medicare coverage for a transplant?
No. Patient coverage and eligibility for transplant are unaffected by this rule.
When does it take effect?
The reconciliation requirement applies to cost reporting periods beginning on or after October 1, 2028. Other provisions take effect with the rest of the FY 2027 rule.
